Click here to read the complete article.
Abstract Title:The effect of microbiome therapy on COVID-19-induced gut dysbiosis: A narrative and系统评价。
摘要来源：
生命科学。 2024年4月1日; 342：122535。 EPUB 2024 2月24日。PMID： 38408636 38408636 Varghese, Shrinidhi Rao, Fahad Zamir, Pradipta Paul, Ali Chaari
Article Affiliation:Mahmoud Yousef
Abstract:AIMS: Emerging evidence highlights the role of COVID-19 in instigating gut dysbiosis, with涉及肺，心脏，大脑和肝脏的疾病严重程度和双向肠道沟通的影响。这项研究旨在评估益生菌，益生元，综合药，A的功效nd fecal microbiota transplantation (FMT) in addressing gut dysbiosis associated with COVID-19, as well as their impact on related disease severity and clinical outcomes.
MATERIALS AND METHODS: We systematically review 27 studies exploring the efficacy of different microbiome-modulating疗法：益生菌，益生元，合成剂和粪便菌群移植作为Covid-19的潜在干预措施。
关键发现：乳杆菌，双歧杆菌，链球菌，肠球菌，pediocococcus，bacillus，saccharomyces和kluyveromyces。这些研究中采用的值得注意的益生元包括栗子单宁，半乳糖糖酸，果糖糖酸，木糖二糖和耐药性葡萄糖。大多数研究的生物学表现出阳性对Covid-19患者的影响，表现出缓解症状，减轻炎症和显着降低死亡率的影响。五项研究报告了死亡率，表明干预组的平均死亡率从0％到11％，而对照组的平均死亡率为3％至30％。具体而言，益生菌，益生元和合成药在减轻症状的持续时间和严重程度时表现出功效，同时显着加速了病毒和症状缓解。 FMT emerged as a particularly effective strategy, successfully restoring gut microbiota and ameliorating gastrointestinal disorders.
SIGNIFICANCE: The insights gleaned from this review significantly contribute to our broader comprehension of the therapeutic potential of biotics in addressing COVID-19-related gut营养不良和缓解次级多器官并发症。